Department of Surgery, Teikyo University, Tokyo, Japan.
Surgery. 2011 Nov;150(5):923-33. doi: 10.1016/j.surg.2011.06.014. Epub 2011 Sep 22.
The Japanese herbal medicine Tokishakuyaku-san (TJ-23) has been used to treat neurodegenerative, immune, and respiratory tract diseases, as well as many gynecologic disorders, with few adverse effects. This study investigated the effect of TJ-23 on alloimmune responses in a murine model of cardiac allograft transplantation.
CBA mice underwent transplantation of a C57BL/6 heart and received oral administration of 2 g/kg per day of TJ-23 or 1 of 16 other commonly used Japanese herbal medicines from the day of transplantation until 7 days afterward. An adoptive transfer study was conducted to determine whether regulatory cells were generated. Histologic and cell proliferation studies, cytokine measurements, and flow cytometry analyses were also performed.
Of the 17 herbal medicines studied, only TJ-23, given in a dose of 2 g/kg per day, induced significantly prolonged allograft survival (median survival time [MST], >100 days). TJ-23 also suppressed proliferation of splenocytes and production of interleukin-2, interleukin-6, and interferon-γ. Adoptive transfer of either whole splenocytes or CD4(+) or CD4(+) CD25(+) cells from TJ-23-treated allograft recipients resulted in indefinite survival of allografts in naive secondary recipients (MST >100 days). Flow cytometry studies showed that the CD4(+) CD25(+) forkhead/winged-helix (FOXP3)(+) regulatory cell population was increased in transplant recipients given TJ-23.
TJ-23 induced hyporesponsiveness to fully allogeneic cardiac allografts and generated CD4(+) CD25(+) regulatory cells in our model.
日本汉方药通仙散(TJ-23)已被用于治疗神经退行性疾病、免疫性疾病和呼吸道疾病,以及许多妇科疾病,且副作用较少。本研究探讨了 TJ-23 对同种异体心脏移植小鼠模型中同种免疫反应的影响。
CBA 小鼠接受 C57BL/6 心脏移植,并于移植后当天开始接受 TJ-23 2g/kg/天或其他 16 种常用日本汉方药中的 1 种的口服治疗,持续至 7 天后。进行了过继转移研究以确定是否产生了调节性细胞。还进行了组织学和细胞增殖研究、细胞因子测量和流式细胞术分析。
在所研究的 17 种草药中,只有 TJ-23 以 2g/kg/天的剂量给药,可显著延长同种异体移植物的存活时间(中位存活时间[MST],>100 天)。TJ-23 还抑制了脾细胞的增殖和白细胞介素-2、白细胞介素-6 和干扰素-γ的产生。来自 TJ-23 治疗的同种异体移植物受者的整个脾细胞或 CD4(+)或 CD4(+) CD25(+)细胞的过继转移导致幼稚的二级受者的同种异体移植物存活时间无限延长(MST>100 天)。流式细胞术研究表明,给予 TJ-23 的移植受者中 CD4(+) CD25(+)叉头/翼状螺旋转录因子(FOXP3)+调节性细胞群增加。
TJ-23 诱导对完全同种异体心脏移植物的低反应性,并在我们的模型中产生 CD4(+) CD25(+)调节性细胞。